. 2020 Aug 10;20:592. doi: 10.1186/s12879-020-05311-0

Table 4.

Univariate and Multivariable Analysis of Factors Associated with TBI Treatment Completion

	Univariate			Multivariable
	OR	95% CI	p	OR	95% CI	p
Elixhauser Comorbidity Index^a
No Comorbidity (Score = 0)	ref
Any Comorbidity (Score ≥ 1)	1.10	[0.77,1.56]	0.61
Diabetes^a
No	ref			ref
Yes	5.46	[1.57,18.94]	0.008	7.27	[1.93,27.30]	0.003
Hypertension^a
No	ref
Yes	1.29	[0.84,1.19]	0.37
Liver Disease^a
No	ref
Yes	1.05	[0.50,2.21]	0.90
HIV^a
No	ref
Yes	0.73	[0.16,3.28]	0.68
Screening Test
Tuberculin Skin Test	ref
Interferon Gamma Release Assay	1.21	[0.80,1.84]	0.37
Year of Arrival
2012	ref
2013	1.50	[0.93,2.41]	0.10
2014	1.32	[0.79,2.18]	0.29
2015	1.12	[0.66,1.89]	0.67
2016	0.99	[0.58,1.70]	0.97
Family Size at Time of Entry
Single	ref			ref
Family of 2–3	1.36	[0.89,2.07]	0.16	1.18	[0.74,1.87]	0.49
Family of > 3	1.05	[0.71,1.56]	0.80	1.11	[0.70,1.74]	0.66
Sex
Female	ref			ref
Male	1.01	[0.72,1.43]	0.06	1.02	[0.74,1.49]	0.90
Region of Origin
Sub-Saharan Africa	ref			ref
South-eastern Asia	2.10	[1.34,3.29]	0.001	2.30	[1.43,3.70]	0.001
Southern Asia	1.63	[1.05,2.58]	0.03	1.64	[1.02,2.64]	0.04
Western Asia	0.88	[0.44,1.77]	0.72	0.64	[0.29,1.38]	0.25
Other	2.00	[0.84,4.79]	0.12	2.33	[0.92,5.94]	0.08
Smoking History
No	ref
Yes	0.92	[0.47,1.79]	0.80
Flu Shot Received
No	ref			ref
Yes	1.51	[1.08,2.12]	0.02	1.65	[1.14,2.40]	0.008
Regimen
9H: Isoniazid only	ref			ref
3HP: Isoniazid + Rifapentine	1.33	[.087,2.04]	0.19	1.58	[0.99,2.51]	0.05
4R: Rifampin	1.49	[0.47,4.79]	0.50	1.47	[0.42,5.10]	0.54
Multiple regimens	1.65	[0.75,3.61]	0.21	1.54	[0.68,3.47]	0.30
Time to Appointment, days
Screened after 11 vs 28 days	0.49	[0.28,0.86]	0.01	0.47	[0.26,0.86]	0.01
Screened after 14 vs 28 days	0.61	[0.41,0.91]	0.01	0.48	[0.27,0.86]	0.01
Distance to TB Clinic, miles	0.92	[0.82,1.03]	0.16
Age^b	1.00	[0.99,1.01]	0.79	1.00	[0.99,1.02]	0.63

^aElixhauser Comorbidity Score and individual comorbidities were run in separate models

^bOdds expressed as change per one year increase in age